Recently, Shanghai Baiyang Pharmaceutical Co., Ltd. (hereinafter referred to as "Baiyang Pharmaceutical") welcomed distinguished guests. Mr. Zhu Qianghua, Deputy Secretary of the Party Committee and General Manager of New Changning Group, led a delegation to visit and guide our company, receiving a warm welcome from Mr. Zhu Xiaowei, Chairman of Baiyang Pharmaceutical, and the company's management team.

The purpose of this visit was to deepen understanding, promote communication, and jointly explore development opportunities in the biopharmaceutical industry. Accompanied personally by Chairman Zhu Xiaowei, General Manager Zhu Qianghua first visited the Baiyang Pharmaceutical Achievement Exhibition Center. Inside the exhibition hall, the company’s guide provided General Manager Zhu with a detailed introduction to Baiyang Pharmaceutical’s development history, corporate vision, core product lines, and innovative achievements in the field of advanced formulation research and development. The guide emphasized the company’s construction of a complex formulation technology platform, international strategic layout, and future plans in the biopharmaceutical sector. General Manager Zhu expressed appreciation for Baiyang Pharmaceutical’s demonstrated technological innovation strength and international development perspective.

During the visit, both parties engaged in in-depth and friendly exchanges on topics of mutual interest such as industrial policies, technological innovation, and market prospects. General Manager Zhu stated that New Changning Group will continue to optimize the business environment to provide a high-quality development foundation for innovative enterprises like Baiyang Pharmaceutical.

The visit concluded successfully in a harmonious atmosphere. The company’s management expressed gratitude to New Changning Group, as an important shareholder, for its ongoing trust and support, and believes that with the joint support of shareholders, Baiyang Pharmaceutical can continue to promote the modernization of traditional Chinese medicine, accelerate the transformation of innovative achievements, and ultimately achieve sustained enhancement of corporate value. Both parties expressed their anticipation for broader exchanges and cooperation opportunities in the future to achieve mutual progress.

Shanghai Baiyang Pharmaceutical Co., Ltd.

September 9, 2025